Five Cancer Treatments Available at CHIPSA – But NOT the Rest of the World
The world has come a long way in the last few decades in its ability to treat cancer. Yet many people still die from the disease, creating growing frustrations regarding the lack of treatment options. It seems as if the standard of care protocols have remained unchanged for 30 years: chemotherapy, radiation and surgery. Furthermore, […]
Continue readingFrom Wheelchair To Walking! How Amanda L. Beat Stage 3 Cancer at CHIPSA!
Amanda L. was diagnosed with an aggressive bone cancer called chondroblastic osteosarcoma in March of 2017. By the time her doctors discovered it, the disease had metastasized and advanced to stage 3. Amanda was told it was non-curative. But nearly two years after her initial diagnosis, Amanda is still alive to share her story, and remarkably, […]
Continue readingFour Cancer Treatments Available at CHIPSA – But NOT the Rest of the World
The world has come a long way in the last few decades in its ability to treat cancer. Yet many people still die from the disease, creating growing frustrations regarding the lack of treatment options. It seems as if the standard of care protocols have remained unchanged for 30 years: chemotherapy, radiation and surgery. Furthermore, […]
Continue readingAnn Celebrates 25 Years Of Healing! 9 Tips From Stage 4 Breast Cancer Survivor
Ann Beat Cancer With No Chemo or Radiation! 9 Tips From A 25 Year Stage 4 Breast Cancer Survivor (Ann received treatment from CHIPSA Hospital back in 1995 and has been free from breast cancer for over 25 years. She has used her healing as a catalyst to help others who are currently battling cancer.) […]
Continue readingA Whole Body Approach: Why CHIPSA Integrates The Power of the Mind to Heal Cancer
CHIPSA Hospital is known for it’s immunotherapy-based treatments that incite the body’s own, powerful immune system to fight off disease. Our methods are focused on harnessing the tools already available within the patient’s own body, and that includes the entire body, even the mind. Patients at CHIPSA are not only receiving […]
Continue readingFrom Wheelchair To Walking! How Amanda D. Beat Stage 3 Cancer at CHIPSA!
Amanda Leverett Davis was diagnosed with an aggressive bone cancer called chondroblastic osteosarcoma in March of 2017. By the time her doctors discovered it, the disease had metastasized and advanced to stage 3. Amanda was told it was non-curative. But nearly two years after her initial diagnosis, Amanda is still alive […]
Continue readingKeytruda Now FDA-Approved for Patients with Melanoma
The KEYNOTE-054 Phase 3 clinical trial (NCT02362594) showed that the immune checkpoint inhibitor drug Keytruda decreased the risk of melanoma recurrence or death by 43% in comparison to a placebo drug. The drug has thus been approved by the U.S. Food and Drug Administration (FDA) to treat patients with stage-3 melanoma (cancer has spread to […]
Continue readingResearch Team Discovers New Immune “Checkpoint” Protein
A recent report in the journal Cell showed that a team led by Vanderbilt researchers has found a new “checkpoint” protein on immune system cells in active, malignant tumors. In mouse models, blocking this protein, along with using other treatments, has been an effective approach to treating cancerous cells. Checkpoint proteins are an important component of […]
Continue readingStudy Shows Better Immunotherapy Outcomes in Tumors with More Mutations
A recent study published in Nature Genetics called “Tumor mutational load predicts survival after immunotherapy across multiple cancer types” revealed that tumors with more mutations had better results with immunotherapy treatment. The study looked at data from 1,662 metastatic cancer patients who received checkpoint inhibitor therapy, and data from over 5,000 patients who were not treated […]
Continue readingPhase 3 Trial Tests Tyvyt as Esophageal Cancer Therapy
The ORIENT-15 Phase 3 clinical trial evaluating Tyvyt (sintilimab injection) combined with chemotherapies Taxol (paclitaxel) and Platinol (cisplatin) as treatment for esophageal squamous cell carcinoma is now underway. Tyvyt was developed by Innovent Biologics and Eli Lilly and Company in China as an immune checkpoint inhibitor that will work against PD-1, a protein found on […]
Continue reading